Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment

Blood

Volumn 118, Issue 26, 2011, Pages 6769-6771

  Yri, Olav Erich ^a   Torfoss, Dag ^a   Hungnes, Olav ^b   Tierens, Anne ^a   Waalen, Kristian ^b   Nordøy, Tone ^c   Dudman, Susanne ^b   Kilander, Anette ^b   Wader, Karin Fahl ^d   Østenstad, Bjørn ^a   Ekanger, Roald ^e   Meyer, Peter ^f   Kolstad, Arne ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^f STAVANGER UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; RITUXIMAB;

ADULT; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HUMORAL IMMUNITY; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NONHODGKIN LYMPHOMA; PATIENT CARE; PRIORITY JOURNAL; SWINE INFLUENZA; TREATMENT RESPONSE;

EID: 84255160982     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-372649     Document Type: Article

References (18)

1. Schulz H, Bohlius J, Skoetz N, et al. Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma. Cochrane Database Syst Rev. 2007;(4)CD003805.
2. Habermann TM. Antibody therapy in aggressive lymphomas. Hematology Am Soc Hematol Educ Program. 2007;257-264.
3. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572-2581. (Pubitemid 38758544)
4. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90(6):2188-2195. (Pubitemid 27392702)
5. Walker AR, Kleiner A, Rich L, et al. Profound hypogammaglobulinemia 7 years after treatment for indolent lymphoma. Cancer Invest. 2008;26(4):431-433. (Pubitemid 351601392)
6. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Recomm Rep. 2010;59(RR-8):1-62.
7. Centkowski P, Brydak L, Machala M, et al. Immunogenicity of influenza vaccination in patients with non-Hodgkin lymphoma. J Clin Immunol. 2007;27(3):339-346. (Pubitemid 46790814)
8. Nordoy T, Aaberge IS, Husebekk A, et al. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med Oncol. 2002;19(2):71-78. (Pubitemid 34625928)
9. Rousseau B, Loulergue P, Mir O, et al. Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study [published online ahead of print May 16, 2011]. Ann Oncol. doi:10.1093/annonc/mdr141.
10. Brydak LB, Machala M, Centkowski P, Warzocha K, Bilinski P. Humoral response to hemagglutinin components of influenza vaccine in patients with non-Hodgkin malignant lymphoma. Vaccine. 2006;24(44):6620-6623. (Pubitemid 46107150)
11. Gelinck LB, Teng YK, Rimmelzwaan GF, van den Bemt BJ, Kroon FP, van Laar JM. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402- 1403. (Pubitemid 47492493)
12. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K. Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop. 2009;49(1):9-13.
13. van der Kolk LE, Baars JW, Prins MH, van Oers MH. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257-2259. (Pubitemid 35001266)
14. Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin's lymphoma patients treated with rituximab-containing regimens. J Immunol. 2011;186(10):6044-6055.
15. Kendall A, Pereira M, Skehel JJ. Concepts and procedures for laboratory-based influenza surveillance. Atlanta, GA: United States Department of Health and Human Services, Public Health Service, Centers for Disease Control; 1982.
16. Yin JK, Khandaker G, Rashid H, Heron L, Ridda I, Booy R. Immunogenicity and safety of pandemic influenza A (H1N1) 2009 vaccine: systematic review and meta-analysis. Influenza Other Respi Viruses. 2011;5(5):299-305.
17. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet. 2011;377(9759):42-51.
18. van Oers MH, Van GM, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol. 2010;28(17):2853-2858.